Moderna, Inc.
About Moderna, Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $1.9B
- Net income
- -$2.8B
- Total assets
- $12.3B
- Market cap
- $18.8B
- Gross margin
- 55.3%
- Operating margin
- -158.1%
- Net margin
- -145.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.9B
- Cost of revenue
- $868.0M
- Gross profit
- $1.1B
- Operating expenses
- $4.2B
- Operating income
- -$3.1B
- Income tax
- $54.0M
- Net income
- -$2.8B
- EPS (basic)
- $-7.26
- EPS (diluted)
- $-7.26
Balance sheet
- Total assets
- $12.3B
- Current assets
- $6.5B
- Total liabilities
- $3.7B
- Current liabilities
- $2.0B
- Shareholders’ equity
- $8.7B
Cash flow
- Operating cash flow
- -$1.9B
- Investing cash flow
- $1.9B
- Financing cash flow
- $593.0M
- Net cash flow
- $666.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $18.8B
- EPS (diluted)
- $-7.26
- Shares outstanding
- 395.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $2.8B in FY2025.
- Revenue declined 89% from FY2021 to FY2025.
- Gross margin of 55.3%, net margin -145.2%.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Moderna, Inc..
Write a review
News about Moderna, Inc.
News & sentiment via Polygon.io
